261 related articles for article (PubMed ID: 23357083)
41. Evaluation of affibody molecule-based PNA-mediated radionuclide pretargeting: Development of an optimized conjugation protocol and
Altai M; Westerlund K; Velletta J; Mitran B; Honarvar H; Karlström AE
Nucl Med Biol; 2017 Nov; 54():1-9. PubMed ID: 28810153
[TBL] [Abstract][Full Text] [Related]
42. A HER2-binding Affibody molecule labelled with 68Ga for PET imaging: direct in vivo comparison with the 111In-labelled analogue.
Tolmachev V; Velikyan I; Sandström M; Orlova A
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1356-67. PubMed ID: 20130858
[TBL] [Abstract][Full Text] [Related]
43. The influence of Bz-DOTA and CHX-A''-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapy.
Tolmachev V; Wållberg H; Andersson K; Wennborg A; Lundqvist H; Orlova A
Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1460-8. PubMed ID: 19430786
[TBL] [Abstract][Full Text] [Related]
44. Preclinical Evaluation of
Oroujeni M; Rinne SS; Vorobyeva A; Loftenius A; Feldwisch J; Jonasson P; Chernov V; Orlova A; Frejd FY; Tolmachev V
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33803361
[TBL] [Abstract][Full Text] [Related]
45. Targeting of HER2-expressing tumors using 111In-ABY-025, a second-generation affibody molecule with a fundamentally reengineered scaffold.
Ahlgren S; Orlova A; Wållberg H; Hansson M; Sandström M; Lewsley R; Wennborg A; Abrahmsén L; Tolmachev V; Feldwisch J
J Nucl Med; 2010 Jul; 51(7):1131-8. PubMed ID: 20554729
[TBL] [Abstract][Full Text] [Related]
46. Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy.
Vorobyeva A; Westerlund K; Mitran B; Altai M; Rinne S; Sörensen J; Orlova A; Tolmachev V; Karlström AE
Sci Rep; 2018 Jun; 8(1):9643. PubMed ID: 29942011
[TBL] [Abstract][Full Text] [Related]
47. First-in-human validation of enzymolysis clearance strategy for decreasing renal radioactivity using modified [
Zhang M; Kang F; Xing T; Wang J; Ma T; Li G; Quan Z; Yang W; Chen X; Wang J
Eur J Nucl Med Mol Imaging; 2024 May; 51(6):1713-1724. PubMed ID: 38216779
[TBL] [Abstract][Full Text] [Related]
48. HER2-positive tumors imaged within 1 hour using a site-specifically 11C-labeled Sel-tagged affibody molecule.
Wållberg H; Grafström J; Cheng Q; Lu L; Martinsson Ahlzén HS; Samén E; Thorell JO; Johansson K; Dunås F; Olofsson MH; Stone-Elander S; Arnér ES; Ståhl S
J Nucl Med; 2012 Sep; 53(9):1446-53. PubMed ID: 22872744
[TBL] [Abstract][Full Text] [Related]
49. Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors.
Altai M; Liu H; Ding H; Mitran B; Edqvist PH; Tolmachev V; Orlova A; Gräslund T
J Control Release; 2018 Oct; 288():84-95. PubMed ID: 30172673
[TBL] [Abstract][Full Text] [Related]
50. 188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment.
Altai M; Wållberg H; Honarvar H; Strand J; Orlova A; Varasteh Z; Sandström M; Löfblom J; Larsson E; Strand SE; Lubberink M; Ståhl S; Tolmachev V
J Nucl Med; 2014 Nov; 55(11):1842-8. PubMed ID: 25278516
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of a maleimido derivative of NOTA for site-specific labeling of affibody molecules.
Tolmachev V; Altai M; Sandström M; Perols A; Karlström AE; Boschetti F; Orlova A
Bioconjug Chem; 2011 May; 22(5):894-902. PubMed ID: 21443270
[TBL] [Abstract][Full Text] [Related]
52. PET imaging of a
Xu Y; Wang L; Pan D; Yu C; Mi B; Huang Q; Sheng J; Yan J; Wang X; Yang R; Yang M
Br J Radiol; 2019 Dec; 92(1104):20190425. PubMed ID: 31593482
[TBL] [Abstract][Full Text] [Related]
53. Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors.
Orlova A; Tran T; Widström C; Engfeldt T; Eriksson Karlström A; Tolmachev V
Int J Mol Med; 2007 Sep; 20(3):397-404. PubMed ID: 17671747
[TBL] [Abstract][Full Text] [Related]
54. Radionuclide Therapy of HER2-Expressing Human Xenografts Using Affibody-Based Peptide Nucleic Acid-Mediated Pretargeting: In Vivo Proof of Principle.
Westerlund K; Altai M; Mitran B; Konijnenberg M; Oroujeni M; Atterby C; de Jong M; Orlova A; Mattsson J; Micke P; Karlström AE; Tolmachev V
J Nucl Med; 2018 Jul; 59(7):1092-1098. PubMed ID: 29439013
[TBL] [Abstract][Full Text] [Related]
55. Tumor targeting using affibody molecules: interplay of affinity, target expression level, and binding site composition.
Tolmachev V; Tran TA; Rosik D; Sjöberg A; Abrahmsén L; Orlova A
J Nucl Med; 2012 Jun; 53(6):953-60. PubMed ID: 22586147
[TBL] [Abstract][Full Text] [Related]
56. Imaging of insulinlike growth factor type 1 receptor in prostate cancer xenografts using the affibody molecule 111In-DOTA-ZIGF1R:4551.
Tolmachev V; Malmberg J; Hofström C; Abrahmsén L; Bergman T; Sjöberg A; Sandström M; Gräslund T; Orlova A
J Nucl Med; 2012 Jan; 53(1):90-7. PubMed ID: 22173843
[TBL] [Abstract][Full Text] [Related]
57. Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of
Dahlsson Leitao C; Rinne SS; Mitran B; Vorobyeva A; Andersson KG; Tolmachev V; Ståhl S; Löfblom J; Orlova A
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30832342
[TBL] [Abstract][Full Text] [Related]
58. Stability Enhancement of a Dimeric HER2-Specific Affibody Molecule through Sortase A-Catalyzed Head-to-Tail Cyclization.
Westerlund K; Myrhammar A; Tano H; Gestin M; Karlström AE
Molecules; 2021 May; 26(10):. PubMed ID: 34066245
[TBL] [Abstract][Full Text] [Related]
59. Optimized Molecular Design of ADAPT-Based HER2-Imaging Probes Labeled with
Lindbo S; Garousi J; Mitran B; Vorobyeva A; Oroujeni M; Orlova A; Hober S; Tolmachev V
Mol Pharm; 2018 Jul; 15(7):2674-2683. PubMed ID: 29865791
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
